1. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
- Author
-
Wang, E, Montesinos, P, Minden, M, Lee, J, Heuser, M, Naoe, T, Chou, W, Laribi, K, Esteve, J, Altman, J, Havelange, V, Watson, A, Gambacorti-Passerini, C, Patkowska, E, Liu, S, Ruishan, W, Philipose, N, Hill, J, Gill, S, Rich, E, Tiu, R, Wang, Eunice S, Montesinos, Pau, Minden, Mark D, Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K, Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E, Gill, Stanley C, Rich, Elizabeth Shima, Tiu, Ramon V, Wang, E, Montesinos, P, Minden, M, Lee, J, Heuser, M, Naoe, T, Chou, W, Laribi, K, Esteve, J, Altman, J, Havelange, V, Watson, A, Gambacorti-Passerini, C, Patkowska, E, Liu, S, Ruishan, W, Philipose, N, Hill, J, Gill, S, Rich, E, Tiu, R, Wang, Eunice S, Montesinos, Pau, Minden, Mark D, Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K, Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E, Gill, Stanley C, Rich, Elizabeth Shima, and Tiu, Ramon V
- Abstract
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+ AML ineligible for intensive induction chemotherapy to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or azacitidine (AZA) alone. The primary end point was overall survival (OS). At the interim analysis (August 26, 2020), a total of 123 patients were randomized to treatment (GIL + AZA, n = 74; AZA, n = 49). Subsequent AML therapy, including FLT3 inhibitors, was received by 20.3% (GIL + AZA) and 44.9% (AZA) of patients. Median OS was 9.82 (GIL + AZA) and 8.87 (AZA) months (hazard ratio, 0.916; 95% CI, 0.529-1.585; P = .753). The study was closed based on the protocol-specified boundary for futility. Median event-free survival was 0.03 month in both arms. Event-free survival defined by using composite complete remission (CRc) was 4.53 months for GIL + AZA and 0.03 month for AZA (hazard ratio, 0.686; 95% CI, 0.433-1.087; P = .156). CRc rates were 58.1% (GIL + AZA) and 26.5% (AZA) (difference, 31.4%; 95% CI, 13.1-49.7; P < .001). Adverse event (AE) rates were similar for GIL + AZA (100%) and AZA (95.7%); grade ≥3 AEs were 95.9% and 89.4%, respectively. Common AEs with GIL + AZA included pyrexia (47.9%) and diarrhea (38.4%). Gilteritinib steady-state trough concentrations did not differ between GIL + AZA and gilteritinib. GIL + AZA resulted in significantly higher CRc rates, although similar OS compared with AZA. Results support the safety/tolerability and clinical activity of upfront therapy with GIL + AZA in older/unfit patients with FLT3mut+ AML. This trial was registered at www.clinicaltrials.gov as #NCT02752035.
- Published
- 2022